Guerbet (XPAR:GBT) Current Accrued Expense : €0.0 Mil (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Guerbet Current Accrued Expense?

Guerbet's Current Accrued Expense for the quarter that ended in Dec. 2023 was €0.0 Mil.

Guerbet Current Accrued Expense Historical Data

The historical data trend for Guerbet's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guerbet Current Accrued Expense Chart

Guerbet Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

Guerbet Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Guerbet Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Guerbet Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Guerbet's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Guerbet (XPAR:GBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guerbet SA (XPAR:GBT) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

4G8:Germany

Address

15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420

Website

http://www.guerbet.com

Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.